Accession Number:



Quantitative Phase Microscopy for Real -Time Clinical Determination of Drug Therapy Response in Primary and Metastatic Breast Cancer

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

University of Utah

Personal Author(s):

Report Date:


Pagination or Media Count:



There are no biomarkers that can accurately predict chemotherapy response in advanced cancer patients and less than 10 of patients with a detected targetable mutation are eligible for a clinical trial. There is a need for new diagnostic methods that can accurately stratify high-risk patients to effective, FDA-approved therapies. Our current patient-derived models for assessing tumor drug response involve expanding patient tumor cells as 3D patient derived organoidsPDO in Matrigel or using in vivo drug sensitivity studies with patient-derived xenograft modelsPDX. These experimental models typically exhibit the same phenotype and molecular alterations in vivo and ex vivo and have the same drug responses as in the patient. However, these methods require 1-8 months to obtain drug sensitivity profiles making this impractical for patientcare. In this project, we will develop a functional assay with the new capability to predict cancer cell response to therapy for both population response and single-cell heterogeneity. In year 2 we have validated the technical platform for this work with a panel of cell lines and FDA-approved therapies. Overall, our project will provide real-time feedback to oncologists on overall drug sensitivityresistance and resistant subpopulations.

Subject Categories:

  • Medicine and Medical Research
  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

[A, Approved For Public Release]